Modulation of tumor immunity by protein-mediated O2 delivery
US12285463B2 · kind B2 · utility
0Cited by
18References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 10, 2021 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Dec 10, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N2005/1098
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1α) pathways and non-HIF-1α pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.